Study of angiogenesis in invasive breast carcinoma by morphometry and immunohistochemistry (original) (raw)

Abstract

BackgroundBreast cancer is the leading cause of cancer-related deaths in Asia and is emerging as the commonest female malignancy. Angiogenesis or neovascularization is important for the growth and spread of malignant tumors, and quantitative assessment of angiogenesis may prove valuable in prognostication. This study was undertaken to quantify and explore angiogenesis with immunohistochemistry with CD 34, CD 105, and vascular endothelial growth factor (VEGF), as well as morphometric analysis and correlate with the grades of the invasive breast carcinoma.MethodsAngiogenesis was assessed by morphometry and immunohistochemistry. Seventy cases of invasive ductal carcinoma (IDC) and twenty-five benign cases as controls were included in the study. Morphometry was performed on the CD34 and CD105 (Endoglin) stained representative histologic sections with the use of a computerized digital photomicrograph system using image analyzing software. Morphometric analysis and evaluation of vascular parameters, i.e. microvessel density (MVD), microvessel caliber (VC), and total microvessel boundary density (TVBD), were calculated. Semiquantitative assessment of angiogenesis of VEGF-stained sections was done by scoring. Immunohistochemical staining was correlated with the histological grade of the tumors. MVD, mean VC, TVBD with their mean values, SD, and range were calculated using Statistical Package for The Social Sciences (Version 20). One-way analysis of variance (ANOVA) with Tukey HSD was performed to assess the difference of the parameters for the groups. Spearman rank correlation coefficients ρ were calculated.ResultsThe vascular parameters were significantly more in malignant lesions as compared to benign lesions and showed differences with increasing grade. Grades of breast carcinoma showed a mild positive correlation with VEGF (ρ = 0.467), MVD-CD34 (ρ = 0.422) and VC-CD34 (ρ = 0.482); and moderate positive correlation with TVBD-CD34 (ρ = 0.615), VC-CD105 (ρ = 0.527), and TVBD-CD105 (ρ = 0.354). When these parameters were compared with each other for all four groups, VEGF showed a mild positive correlation with MVD-CD34 (ρ = 0.295), TVBD-CD34 (ρ = 0.339), and TVBD-CD105 ((ρ = 0.277). MVD-CD105 showed a mild positive correlation with MVD-CD34 TVBD-CD105 also showed a strong positive correlation with MVD-CD34. VC-CD105 showed a moderate positive correlation with VC-CD34. CD 105 stained fewer but larger caliber vessels.ConclusionsIn this study, vascular parameters showed significant differences in three grades of IDC with CD34. Differences were seen in vascular parameters stained with CD105 in three grades of IDC. Expression of VEGF also showed significant differences with positive correlations in the three grades of IDC. CD34 highlighted both old and newly formed microvessels. CD 105 stained fewer but larger caliber microvessels. VC-CD105 can be an extremely useful adjunct along with VEGF and CD34 to study angiogenesis of vessels in IDC.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (31)

  1. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pacific J Cancer Prev. 2016;17(S3):43e46.
  2. Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Annals of Surgical Oncology. 2018;25:1783e1785. Springer New York LLC.
  3. Hayes DF. Prognostic and predictive factors revisited. Breast. 2005;14(6):493e499.
  4. Adam Maciejczyk A. New prognostic factors in breast cancer. Adv Clin Exp Med. 2013;22(1):5e15.
  5. Arnes JB, Stefansson IM, Straume O, et al. Vascular proliferation is a prognostic factor in breast cancer. Breast Cancer Res Treat. 2012;133(2):501e510.
  6. Murray JC, Fox SB. Microscopic assessment of angiogenesis in tumors. In: Angiogenesis Protocols. vols. 29e46. Humana Press; 2003.
  7. Safwat MD, Habib F, Elayat A, Oweiss N, Reffat S, Algaidi S. Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast. Folia Morphol (Warsz). 2009;68(3):144e155.
  8. Choi WWL, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF- family gene expression. Mod Pathol. 2005;18:143e152.
  9. Valkovi c T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonji c N. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch. 2002;440(6):583e588.
  10. Zhou S, Wang G-P, Liu C, Zhou M. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer. 2006;6:231.
  11. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB Journal. 2003;17(9):984e992.
  12. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor- associated angiogenetic blood vessels. Oncogene. 2003;22(42):6557e6563.
  13. Charpin C, Dales JP, Garcia S, et al. Neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res. 2004;10:5815e5819.
  14. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403e410.
  15. Qureshi A, Pervez S. Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers. J Pak Med Assoc. 2010 May;60(5):350e353.
  16. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018 Nov;142(11):1364e1382.
  17. Olewniczak S, Chosia M, Kwas A, Kram A, Domagała W. Angiogenesis and some prognostic parameters of invasive ductal breast carcinoma in women. Pol J Pathol. 2002;53(4):183e188.
  18. Popiela TJ, Sikora J, Klimek M, et al. The analysis of CD34 antigen immunoreactivity level in invasive ductal breast cancer with respect to the presence of lymph node metastases. Neuroendocrinol Lett. 2008;29(4):443e446.
  19. S ‚ ener E, S ‚ ipal S, Gu ¨ndo gdu C. Comparison of microvessel density with prognostic factors in invasive ductal carcinomas of the breast. Turk Patoloji Derg. 2016;32(3):164e170.
  20. Ding S, Li C, Lin S, et al. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol. 2006;37(7):861e866.
  21. Beresford MJ, Harris AL, Ah-See M, Daley F, Padhani AR, Makris A. The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer. 2006;95(12):1683e1688.
  22. Dales JP, Garcia S, Carpentier S, et al. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol. 2004 Feb;35(2):176e183.
  23. Gabriel CN, Cristina BB, Arlete H, Lı ´gia Maria BC. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105// endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology. 2008;28:17e23.
  24. Adams J, Carder PJ, Downey S, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000;60(11):2898e2905.
  25. Al-Harris ES, Al-Janabi AAA, Al-Toriahi KM, Yasseen AA. Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer. Saudi Med J. 2008;29(8):1099e1104.
  26. Nieto Y, Woods J, Nawaz F, et al. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer. 2007;97(3):391e397.
  27. Callagy G, Dimitriadis E, Harmey J, Bouchier-Hayes D, Leader M, Kay E. Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor. Appl Immunohistochem Mol Morphol. 2000;8(2):104e109.
  28. Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al. Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer. 2005;5:25.
  29. Tsutsui S, Kume M, Era S. Prognostic value of microvessel density in invasive ductal carcinoma of the breast. Breast Cancer. 2003;10(4):312e319. https://doi.org/10.1007/ bf02967651.
  30. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992 Nov 7;340(8828):1120e1124. https://doi.org/ 10.1016/0140-6736(92)93150-l. PMID: 1279332.
  31. Nassiri F, Cusimano MD, Scheithauer BW, et al. Anticancer Res. 2011;31(6):2283e2290.